Your Article Summary
Valsartan for Prevention of Recurrent Atrial Fibrillation
New England Journal of Medicine, 04/16/09
Atrial fibrillation is the most common cardiac arrhythmia, and no current therapy is ideal for control of this condition. Experimental studies suggest that angiotensin II–receptor blockers (ARBs) can influence atrial remodeling, and some clinical studies suggest that they may prevent atrial fibrillation. Treatment with valsartan was not associated with a reduction in the incidence of recurrent atrial fibrillation.
Related Articles
Atrial Fibrillatory Wall Motion and Degree of Atrial Remodeling in Patients with Atrial Fibrillation: A Tissue Velocity Imaging Study
Journal of Cardiovascular Electrophysiology, 10/28/09
Relevance Score: 70%
Catheter Ablation of Supraventricular Arrhythmias and Atrial Fibrillation
American Family Physician, 11/12/09
Relevance Score: 69%
Sudden atrial fibrillation associated with acute alcohol ingestion and cor triatriatum
Baylor UMC Proceedings, 10/27/09
Relevance Score: 69%
Oral anticoagulant therapy safely prevented stroke in older patients with atrial fibrillation
Evidence-Based Medicine, 10/26/09
Relevance Score: 69%
Glucocorticoid Use and Risk of Atrial Fibrillation or Flutter
Archives of Internal Medicine, 10/14/09
Relevance Score: 69%
Today in Cardiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Update on the everolimus-eluting coronary stent system: results and implications from the SPIRIT clinical trial program
Vascular Health and Risk Management, 12/16/09
Red Blood Cell Distribution Width and Risk of Cardiovascular Events and Mortality in a Community Cohort in Taiwan
American Journal of Epidemiology, 12/16/09
Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction
Circulation, 12/16/09

See Latest Articles